{
    "2020-12-22": [
        [
            {
                "time": "2020-12-31",
                "original_text": "医药生物行业跨市场周报：2020年医保谈判结束 BIOTECH和创新药路在何方？",
                "features": {
                    "keywords": [
                        "医保谈判",
                        "BIOTECH",
                        "创新药"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-12-31",
                "original_text": "2020MNC中国区业绩大比拼：默沙东升档、罗氏受创医保、赛诺菲新品青黄不接",
                "features": {
                    "keywords": [
                        "默沙东",
                        "罗氏",
                        "赛诺菲",
                        "医保",
                        "业绩"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "跨国企业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-12-31",
                "original_text": "【天风医药】智飞生物：与默沙东续签代理协议，奠定未来2-3年快速增长基调",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "默沙东",
                        "代理协议",
                        "快速增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-01",
                "original_text": "医疗板块2021年度策略：把握三大主线",
                "features": {
                    "keywords": [
                        "医疗板块",
                        "年度策略",
                        "三大主线"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-01-05",
                "original_text": "疫苗板块拉升，复星医药、康希诺-U、智飞生物、沃森生物、长春高新纷纷上扬",
                "features": {
                    "keywords": [
                        "疫苗板块",
                        "复星医药",
                        "康希诺-U",
                        "智飞生物",
                        "沃森生物",
                        "长春高新"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-06",
                "original_text": "医药生物行业周报：“三重行业红利 五重公司催化”助推智飞生物 强调Q1医药躁动机会",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业红利",
                        "公司催化",
                        "智飞生物",
                        "Q1躁动机会"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-03-01",
                "original_text": "医药板块2021年春季行情如何？",
                "features": {
                    "keywords": [
                        "医药板块",
                        "春季行情"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}